The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial
Open accessAbstract
Background Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with this disease.Methods In a multicentre clinical trial, six male patients (aged 35-63 years) with choroideremia were administered AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection). Visual function tests included best corrected visual acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. This study is registered with ClinicalTrials.gov, number NCT01461213.Findings Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within one to three letters. Mean gain in visual acuity overall was 3·8 letters (SE 4·1). Maximal sensitivity measured with dark-adapted microperimetry increased in the treated eyes from 23·0 dB (SE 1·1) at baseline to 25·3 dB (1·3) after treatment (increase 2·3 dB [95% CI 0·8-3·8]). In all patients, over the 6 months, the increase in retinal sensitivity in the treated eyes (mean 1·7 [SE 1·0]) was correlated with the vector dose administered per mm(2) of surviving retina (r=0·82, p=0·04). By contrast, small non-significant reductions (p>0·05) were noted in the control eyes in both maximal sensitivity (-0·8 dB [1·5]) and mean sensitivity (-1·6 dB [0·9]). One patient in whom the vector was not administered to the fovea re-established variable eccentric fixation that included the ectopic island of surviving retinal pigment epithelium that had been exposed to vector.Interpretation The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment. These findings lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset of retinal thinning.Funding UK Department of Health and Wellcome Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, wild-type AAV-based gene therapies for ophthalmologic indications generally require relatively high doses and/or administration via subretinal injection, an invasive surgical procedure that requires detachment of photoreceptors from the RPE and reportedly results in transduction of <5% of the retinal surface. 25 – 27”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, a recent phase I trial for choroideremia showed promising signs of efficacy.15”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Adeno-associated virus has been successful in clinical gene therapy trials for Leber's congenital amaurosis, hemophilia, familial lipoprotein lipase deficiency, and choroideremia.8–15,26,27,60,61”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“A different approach to subretinal injection is a 'two-step ' injection with initiation of a small 'pre-bleb ' using balanced saline solution (BSS) followed by slow propagation of the bleb using the viral vector (MacLaren et al., 2014). A considerable advantage of two-step injection is that it allows bleb propagation at a lower injection pressure (Scruggs et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as MacLaren et al., 2014
In the citing paper
“Significant inflammation was also observed at 1 × 1011 vg in clinical trials for choroideremia.90,102”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [102]
In the citing paper
“Injection protocols dating to 2014 (30, 31) called for a 2-step procedure, which largely avoids causing a break in Bruch's membrane but does not completely eliminate the risk (20, 32).”
From Subretinal therapy: technological solutions to surgical and immunological challenges (2022) · cites this paper as [30]
In the citing paper
“while subretinal viral gene therapy has a favourable safety profile [300]”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [300]
In the citing paper
“A phase I/II clinical trial of subretinal gene therapy using an AAV2 vector to deliver human REP1 to the outer retina has shown sustained preservation or improvement of visual acuity over 2 to 5 years in patients with advanced disease [MacLaren 2014, Xue 2018].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as MacLaren 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Sieving, P. A., Caruso, R. C., Tao, W., Coleman, H. R., Thompson, D. J. S., Fullmer, K. R., & Bush, R. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600236103 · Cited by 591
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Świder, M., Iwabe, S., Román, A. J., Olivares, M. B., Schwartz, S., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 441
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337
Self-citationCloning of a gene that is rearranged in patients with choroideraemia
Cremers, F. P. M., van de Pol, D. J. R., van Kerkhoff, L. P. M., Wieringa, B., & Ropers, H.-H. (1990) · Nature · doi:10.1038/347674a0 · Cited by 333
Self-citationLoeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279
Cited by
Sorted by citations
Items 701–795 of 795
PERIPHERAL OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN A CHOROIDEREMIA CARRIER
Corvi, F., Corradetti, G., Wong, A., Eng, J. G., & Sadda, S. R. (2020) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001109 · Cited by 1
Suprachoroidal Delivery of Subretinal Gene and Cell Therapy
Xu, D. N., Ma, K., & Ho, A. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-76853-9_9 · Cited by 1
Chorioretinopathies: Choroideraemia and Gyrate Atrophy
Leroy, B. P. (2014) · Springer eBooks · doi:10.1007/978-3-540-69466-3_15 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
A Genotype - Phenotype Study of Childhood Onset Retinal Dystrophies
Borman, A. D. (2016) · UCL Discovery (University College London) · Cited by 1
Morgan, J. I. W., Jiang, Y. Y., Vergilio, G. K., Serrano, L. W., Pearson, D. J., Bennett, J., Maguire, A. M., & Alemán, T. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.17.459817 · Cited by 1
Hallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2024) · medRxiv · doi:10.1101/2024.06.12.24308796 · Cited by 1
Self-citationHallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2024) · eLife · doi:10.7554/elife.99806.1 · Cited by 1
Self-citationSlama, M. C. C. (2015) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Pediatric genetic macular and choroidal diseases
Bergman, M. Y., & Nallasamy, S. (2015) · Journal of Pediatric Genetics · doi:10.3233/pge-14106
Gene Therapy and Viral Vectors
Taylor, M. W. (2014) · Springer eBooks · doi:10.1007/978-3-319-07758-1_18
Fresh from the designation pipeline: orphan drugs recently designated in the EU (June–July 2014)
Antoniu, S. A. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.987123
Promising results in a gene therapy trial for retinal disease
Bible, E. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.18
Clinical update in optic nerve disorders
Agarwal, N., Hanumunthadu, D., Afrasiabi, M., Malaguarnera, G., & Cordeiro, M. F. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1003544
Gene Therapy – A Current Review.
Yadav, S., & Sir, J. (2014) · International Journal Of Medical Science And Clinical Invention
Gene Therapy for Retinal Diseases Is Within Sight
Wykoff, C. C. (2014)
ประโยชนทย Applications of genetic engineering in medicine
Yeetong, P., & Tammachote, R. (2015)
Anti-Angiogenic Gene Therapy: Basic Science and Challenges for Translation into the Clinic
Lange, C., & Bainbridge, J. W. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_11
Macular Dystrophies: Management and Interventions
Marazova, K., & Sahel, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-26621-3_11
Ocular Gene Therapy—The Future Is Now
Huang, S. S., High, K. A., & Toso, R. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000216
Development of Helper-Dependent Adenoviral Vectors for Gene Therapy for Inherited Retinal Diseases
Lam, S. (2015) · TSpace (University of Toronto)
Novel technologies and their applications in biotechnology
Deeni, Y., Beccari, T., Dündar, M., Gartland, J. S., Maffia, M., Viola-Magni, M., & Gartland, K. M. A. (2014) · ResearchOnline
A Promise of Vision Restoration
Gauvain, G., Chaffiol, A., Duebel, J., & Picaud, S. A. (2017) · Cambridge University Press eBooks · doi:10.1017/9781107281875.026
The Next Generation Sequencing Based Molecular Diagnosis of Visual Diseases
Wang, X., & Lewis, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56418-0_4
Gentherapie zur Behandlung von Netzhauterkrankungen
Ochakovski, G. A., Bartz‐Schmidt, K. U., & Fischer, M. D. (2017) · Medizinische Genetik · doi:10.1007/s11825-017-0133-7
Sobre la terapia génica para enfermedades de la retina
Fischer, M. D. (2017) · Ophthalmologica · doi:10.1159/000477516
Contribution of non-coding mutations to RPGRIP1 -mediated inherited retinal degenerationPreprint
Jamshidi, F., Place, E., Mehrotra, S., Navarro-Gomez, D., Maher, M., Valkanas, E., Cherry, T. J., Lek, M., MacArthur, D. G., Pierce, E. A., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/211292
Zaminpira, S. (2017) · Open Access Journal of Surgery · doi:10.19080/oajs.2017.06.555687
Moshiri, A., & Yazdanyar, A. (2018) · Current practices in ophthalmology · doi:10.1007/978-981-10-8545-1_5
Hagerman, G. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3m32ng1v
Romano, F., Arrigo, A., & Parodi, M. B. (2018) · European Ophthalmic Review · doi:10.17925/eor.2018.12.1.45
Introducing the Evolutionary Cell Memory (ECM) Hypothesis
Zaminpira, S. (2018) · International Journal of Biochemistry & Physiology · doi:10.23880/ijbp-16000117
Molecular insights into PCARE-associated retinal disease
Serrano, J. C. C. (2018) · Radboud Repository (Radboud University)
Battu (2018) · doi:10.26481/dis.20181221rb
Der natürliche Verlauf der Choroideremie
Seitz, I. P., & Fischer, M. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0841-3417
Engineering of Novel Adeno-Associated Virus Vectors for Gene Therapy Applications
Ortiz, S., & Luis, J. (2016) · Cited by 1
Punzo, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00019-8 · Cited by 1
Tabbarah, S. (2018) · TSpace (University of Toronto)
Gene Therapy and Surgery for Retinal Diseases
Jiang, D. J., Xu, C. L., & Tsang, S. H. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0027221
Gene Therapy for Retinal Disease
McClements, M. E., & MacLaren, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00011-7
Self-citationEmerging Gene Therapy Approaches Under Clinical Investigation for Retinal Degenerative Diseases
Bakall, B., Klein, K. A., & Mears, K. A. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_102
Distortion and Scotoma Assessment in Surgical Macular Diseases
Chen, F. K. (2020) · Springer eBooks · doi:10.1007/978-981-15-7644-7_8
Vanegas-Torres, A. M., Bedoya, C. L., Ramírez-Orozco, J. A., Franco, J. F. G., & Suárez-Escudero, J. C. (2020) · Revista Médicas UIS · doi:10.18273/revmed.v33n2-2020013
Scaria, A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000376
Zuvin, M. (2019) · Sabanci University
iPSCs for modeling choroideremia
Jazouli, Z., Torriano, S., & Kalatzis, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823882-0.00005-9
Genes and Genetics in Ophthalmology
Kannabiran, C. (2022) · Springer eBooks · doi:10.1007/978-981-16-4247-0_1
Khan, M. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-30273-7_11
Nonviral PDMAEMA Vectors Efficiently Express PDE6β in a Mouse Model of Retinitis PigmentosaPreprint
Bitoque, D. B., Calado, S. M., da Costa, A. M. R., & Silva, G. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.538567
New Avenues of Delivery (Subretinal Gene Therapy, Port Delivery, Suprachoroidal)
Nair, A. A., Chaili, S., & Law, J. C. (2023) · Current practices in ophthalmology · doi:10.1007/978-981-99-1661-0_19
Understanding the Biology in Current Cell and Gene Therapy for Treating Macular Diseases
Qiu, T. G. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003722
Multicenter normative data for mesopic microperimetryPreprint
Pfau, M., Jolly, J. K., Charng, J., von der Emde, L. A., Müller, P. L., Ansari, G., Pfau, K., Chen, F. K., & Wu, Z. (2024) · medRxiv · doi:10.1101/2024.02.05.24302327
Chew, L. A., Watson, B. C., & Lad, E. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13820-1.00022-0
Stieger, K., & Lorenz, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-35055-9_15
Targeted Therapy for Neurological Disorders Using Nanomaterial-Based Drug Delivery Vehicle
Sharma, M., Gupta, T., Gupta, N., Rawat, R., Badoniya, N., Pandey, E., & Sharma, S. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0308-1_7
The landscape of clinical trials research in inherited ophthalmic disease
Ng, V., Li, C., Cornes, P., & Votruba, M. (2024) · Ophthalmic Genetics · doi:10.1080/13816810.2024.2378013
Hallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2024) · eLife · doi:10.7554/elife.99806
Self-citationVarela, M. D., Hashem, S. A., Sumodhee, D., & Michaelides, M. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.12.9
Lu, W., Li, S., & Jin, X. K. (2024) · International Conference on Smart Healthcare and Wearable Intelligent Devices (SHWID) · doi:10.1145/3703847.3703883
Hallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2025) · eLife · doi:10.7554/elife.99806.2 · Cited by 1
Self-citationIndications and Surgical Treatments for Inherited Retinal Dystrophies
Ríos, P., & Irigoyen, C. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009100
Inherited chorioretinal disorders
Bianco, L., Antropoli, A., Mansour, A. M., Arrigo, A., Parodi, M. B., & Audo, I. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29084-8.00005-5
MacDonald, I. M., Zhai, F., Xu, M., Radziwon, A., & Seabra, M. C. (2025) · doi:10.1093/med/9780197659403.003.0039
Self-citationShen, L. L., Zhang, Y., Wong, J., Foote, K. G., Porco, T. C., Wang, R. K., Roorda, A., & Duncan, J. L. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.40
Ultrasound-Enhanced Retinal Delivery of Engineered Viral Vectors
Link, S. S., Fan, K., Adame, J., Keehn, C. C., Shen, G., Frankfort, B. J., & Szablowski, J. (2026) · Investigative Ophthalmology & Visual Science · doi:10.64898/2026.01.04.697446
Galdikaitė, E., Krušnauskas, R., Henderson, E., & Bujakowska, K. M. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101462 · Cited by 1
Vitrectomy and internal limiting membrane peeling for extensive macular schisis in choroideremia
Elsayed, M. E. A. A., Barone, V., & MacLaren, R. E. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07162-y
Self-citationCone Contrast and Entropy of Adaptive Optics Images in Choroideremia
Huang, A. M., Xu, P., Cooper, R. F., & Morgan, J. I. W. (2026) · Current Eye Research · doi:10.1080/02713683.2026.2645894
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Deciphering molecular mechanisms of unusual variants in Usher Syndrome
Liquori, A. (2015) · theses.fr (ABES) · doi:10.70675/3bcce956z97eaz41ffz93aczda615888431b
Haidar, Z. (2019) · theses.fr (ABES) · doi:10.70675/3577ad91z4de1z4642zb506zdfe80f5b9c8a
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Applications of Fundus-Tracked Perimetry in the Assessment of Visual Sensitivity
Britten‐Jones, A. C., Dagelet, J., & Ayton, L. N. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5198-8_15
Precision Medicine in Inherited Retinal Disease: Advances, Challenges, and Future Directions
Dhivagaran, T., Butt, F. R., Grover, K., Devgan, K., Sachdeva, K. S., Dhivagaran, V., Abid, F., Tao, B. K.-L., Balas, M., Dimopoulos, I. S., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060292
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Beckwith‐Cohen, B., Sun, K., Occelli, L. M., Winkler, P. A., Somma, A. T., Montiani‐Ferreira, F., Marinho, L. F. L. P., Schall, P. Z., Parys, M., Yuzbasiyan‐Gurkan, V., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201782
Gene therapy in patients with choroideremia: a meta-analysis of clinical trials
Guerrero, P. R., Ridruejo-Ortega, B., González-Barros, D., Silva-Schultz, S., Stalmashka, T., Molinero-Sicilia, L., Benites, G., Rivera‐Izquierdo, M., Usategui-Martín, R., & Pastor‐Idoate, S. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07326-w
Yin, L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016169
Wegweisende Studien in der Augenheilkunde – von der klinischen Studie zur Leitlinientherapie
Seitz, I. P., Ziegler, M., Kahle, N. A., Wilhelm, B., & Peters, T. M. (2026) · Die Ophthalmologie · doi:10.1007/s00347-026-02465-1
Lin, T.-Y., Wang, C.-Y., Chen, L., Ho, H.-Y., & Huang, S.-P. (2026) · Ophthalmic Epidemiology · doi:10.1080/09286586.2026.2700029
Macular holes in inherited retinal dystrophies and vitreoretinopathies
Elsayed, M. E. A. A., Dembélé, M., Marques, J. P., Xue, K., & MacLaren, R. E. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.07.010
Self-citationPerivascular Astrocytic Gliosis Induced by Retinal Gene Therapy
Elsayed, M. E. A. A., Seitz, I. P., Fischer, M. D., & MacLaren, R. E. (2026) · Human Gene Therapy · doi:10.1177/10430342261469741
Self-citationChujo, S., Abbasgholizadeh, R., Alhelaly, M., Nittala, M. G., Quarta, A., Chung, Y.-C., Kwak, H., Soylu, C., Rattu, R., Huang, J., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101388
The subretinal space: from surgical target to therapeutic compartment — A narrative review
Grieco, G., Carlà, M. M., Stefano, G. D., & Tamburrelli, C. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.013
Tissue engineering strategies in retina
Upreti, S., Maitra, N., & Ghosh, M. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33455-9.00015-8
Metadata
- Authors
- MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., Lotery, A. J., Downes, S. M., Webster, A. R., & Seabra, M. C.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Oxford (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Imperial College London (GB)
- Nationwide Children's Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- Radboud University Nijmegen (NL)
- Manchester Academic Health Science Centre (GB)
- University of Southampton (GB)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9923
- Pages
- 1129-1137
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC4171740
- OpenAlex
- W2126115955
- Cited by
- 796
- References
- 28
- Citations by year
- 2026: 24 · 2025: 29 · 2024: 46 · 2023: 42 · 2022: 37 · 2021: 62 · 2020: 68 · 2019: 78 · 2018: 85 · 2017: 109 · 2016: 80 · 2015: 83 · 2014: 51
- FWCI
- 44.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Wellcome Trust (091984)
- Cancer Research UK (11339)
- National Institute for Health and Care Research (NF-SI-0509-10185)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- choroideremia, retinal gene therapy, adeno-associated virus vectors, Rab escort protein 1, CHM gene, X-linked retinal degeneration, visual acuity improvement, retinal sensitivity, microperimetry, retinal detachment, vector dose, rod and cone function, retinal pigment epithelium, eccentric fixation, blindness treatment
- MeSH terms
- Adenoviridae, Adult, Aged, Fluorescence, Genetic Vectors, Humans, Male, Middle Aged, Retinal Detachment, Visual Acuity, Genetic Therapy, Choroideremia, Gene Transfer Techniques, Transgenes, Adaptor Proteins, Signal Transducing, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
